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Dynamic changes in chromatin structure through ATP-de-
pendent remodeling and covalent modifications on histones
play important roles in transcription regulation. Among the
many chromatin modifiers identified, the NuRD (nucleosome
remodeling histone deacetylase) complex is unique because it
possesses both nucleosome remodeling and histone deacetylase
activities. To understand the biological function of the NuRD
complex, we generated a knock-out mouse model of the Mta2
(metastasis-associated protein 2) gene, which encodes a NuRD-
specific component. Mta2 null mice exhibited partial embry-
onic lethality. The surviving mice developed lupus-like autoim-
mune symptoms including skin lesions, bodyweight loss,
glomerulonephritis, liver inflammation, and production of
autoantibodies. Transplantation of bone marrow cells from
Mta2 null mice recapitulated some of the symptoms including
skin lesion and bodyweight loss in the recipient mice. Mta2
null T lymphocytes showed normal development but hyper-
proliferation upon stimulation, which correlates with hyper-
induction of interleukin (IL)-2, IL-4, and interferon (IFN)-.
T cell hyperproliferation, but not other autoimmune symp-
toms, was observed in T cell-specific Mta2 knock-out mice.
Mta2 null T cells produced more IL-4 and IFN- under Th2
activation conditions, but normal levels of IL-4 and IFN-
under Th1 activation conditions. Furthermore, we found that
IL-4 is a direct target gene of Mta2. Our study suggests that
Mta2/NuRD is involved in modulating IL-4 and IFN- expression
in T cell immune responses, and gene expression in non-T cells
plays an important role in controlling autoimmunity.
Dynamic changes in chromatin structure through ATP-de-
pendent remodeling and covalent histone modifications play
important roles in regulating gene expression. Studies in recent
years have identified many ATP-dependent chromatin remod-
eling and histone modifying enzymes (1–3). Among them, the
NuRD (nucleosome remodeling histone deacetylase) complex
is of special interest because it possesses both nucleosome
remodeling and histone deacetylase activities (4).
The major components of the mammalian NuRD complex
include Mi-2, Mta2 (metastasis-associated protein 2),
HDAC1/2,3 RbAp46/48, and Mbd3 (5, 6). HDAC1/2 and
RbAp46/48 form a deacetylase core complex that exists in both
NuRDand the Sin3Ahistone deacetylase complex (6–8).How-
ever, Mi-2, Mbd3, and Mta2 appear to be unique for the
NuRD complex (4, 9).Mi-2 is an ATP-dependent nucleosome
remodeling enzyme (10). Studies in Drosophila and Caenorh-
abditis elegans indicate that Mi-2 is involved in Hox gene
silencing and somatic cell differentiation (11, 12). In mamma-
lian cells, Mi-2 has been shown to interact with a master lym-
phocyte transcription factor Ikaros (13). Mbd3 is a member of
the Mbd (methyl-CpG-binding domain) containing protein
family. It interacts with Mbd2, which in turn can recruit the
NuRD complex to repress transcription of methylated DNA (8,
14). Recent studies have also shown that Mbd3 is required for
pluripotency of embryonic stem cells (15, 16).
In mammalian cells, Mta2 belongs to theMta protein family,
which also includes Mta1 and Mta3. In vitro studies demon-
strated that MTA2 positively regulates HDAC activity (8). The
C. elegans Mta2 homolog, egl-27 together with other NuRD
component homologs have been shown to antagonize the Ras
signaling pathway during vulval development (17). In addition
to Mta2, Mta3 has also been shown to form a complex with
other NuRD components and play important roles in invasive
growth of breast cancer cells through repressing Snail gene
transcription, and in B cell differentiation through the Bcl-6
transcription repressor (9, 18). Mta1 gene overexpression has
been associated with cancer metastasis (19, 20), although
whether it functions together with other NuRD components is
not clear. Compared withMta1 andMta3,Mta2 is more ubiq-
uitously expressed. It is likely that different Mta family members
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Chromatin remodeling and histone modifications have been
shown to play crucial roles in transcription regulation in the
immune system (21). Previous studies have established that
during T helper (Th) cell differentiation, expression of specific
transcription factors, such as T-bet andGATA3, and cytokines,
such as IFN- and IL-4, are regulated at the chromatin level
(21–23). For example, histone hyperacetylation has been
observed at the IFN- regulatory region in Th1 cells and at the
IL-4 regulatory region inTh2 cells (24, 25). DNAdemethylation
at IL-4 promoters and the regulatory region have also been
observed in Th2 differentiation (23, 26). Even though it is well
established that histone modification and chromatin remodel-
ing play important roles in lymphocyte differentiation and acti-
vation, little is known about the identity of the corresponding
enzymes. Several recent reports have indicated a role of the
NuRD complex in these processes. For example, deficiency in
Mbd2, a NuRD-interacting methyl-CpG-binding protein,
results in abnormal Th cell differentiation and abnormal IL-4
expression (27). Another NuRD interacting protein, Ikaros, has
been shown to set thresholds for T cell activation and TCR-
mediated T cell differentiation (8). However, a direct link
between NuRD and T cell function has yet to be established.
To understand the in vivo function of Mta2/NuRD, we have
generated Mta2 knock-out mice. Mta2 null mice exhibit mul-
tiple phenotypes including partial embryonic lethality, devel-
opment defects, and more interestingly, a lupus-like autoim-
mune disease. This report focuses on characterizing the
autoimmune phenotypes and T lymphocyte function in adult
Mta2 null mice. Our data revealed the important role of Mta2/
NuRD in regulating IL-4 and IFN- expression during Th2-
prone immune response and in regulating gene expression in
non-T cells to control autoimmunity.
EXPERIMENTAL PROCEDURES
Generation of Mice Carrying Mta22lox and Mta21lox Alleles
and Manipulation of Mice—The Mta2 targeting vector
included PGK-Neo and MC1-tk expression cassettes for posi-
tive and negative selection, respectively. Two FRT sites were
inserted to each side of the PGK-Neo minigene for future
removal of the expression cassette by FLP recombinase. Two
loxP sites were inserted in introns 3 and 11, respectively, to
flank the region including the PGK-Neo cassette and the
genomic sequence from exons 4 to 11. LinearizedMta2 target-
ing vector was electroporated into J1 ES cells (129SvJ) and
selected in the presence of G418 and FIAU (1-(2-deoxy-2-
fluoro--D-arabinofuranosyl)-5-iodouracil). Correctly tar-
geted ES cell clones identified by PCR screens were expanded
and injected into C57Bl/6 blastocysts to obtain chimeric mice,
which were then bred to C57Bl/6 to produce C57Bl/6/129SvJ
hybrid F1 progeny carrying theMta22lox allele. Mice heterozy-
gous for the Mta22lox allele were crossed with EIIa Cre trans-
genic mice to generate mice carrying the Mta21lox allele in
which Cre recombinase-mediated loxP recombination had
occurred and removed the PGK-Neo cassette as well as the
genomic sequence from exons 4 to 11. The primers (set a in Fig.
1B) for genotyping Mta2 wild-type (WT) and Mta22lox alleles
are the 5 sequence 5-GCTGAAGCAGACAGCAAAC-3 and
3 sequence, 5-CATGCCAGGTTTTGAACCC-3. PCR was
performed as follows: 94 °C at 3 min followed by 35 cycles of:
94 °C for 30 s, 55 °C for 30 s, 72 °C for 45 s, and then one cycle
at 72 °C for 7 min. A 390-bp fragment is derived from the
mutant allele and a 335-bp fragment is derived from the wild-
type allele. The primers (set b in Fig. 1B) for genotyping the
Mta21lox allele are the 5 sequence, 5-GCTGACAGTAAT-
GCTCGTGAGT-3 and the 3 sequence, 5-ATGCTTCTCACT-
GAGCTACAGC-3, and the fragment is 1.2-kb. PCR was per-
formed as follows: 94 °C for 3 min followed by 35 cycles of: 94 °C
for 30 s, 60 °C for 45 s, 72 °C for 90 s, and thenone cycle at 72 °C for
7min. A 1.5-kb fragment is derived from theMta21lox allele.
TheMta2 null and controlmice described in this report were
on amixed genetic background (129SvJ and C57Bl/6). EIIa-Cre
(28) transgenic mice were purchased from the Jackson Labora-
tory and the LckCre transgenic mice were obtained from the
laboratory of Zhuang Yuan at Duke University (24). Themouse
maintenance and experimentswere done following theUniversity
of North Carolina Institutional Animal Care and Use Committee
approved protocols. The skin and liver tissues from control and
Mta2 knock-out mice were fixed in formalin for 20–24 h and
embedded in paraffin. Tissue sections (5 m) were stained with
hematoxylin and eosin (H&E) for morphological examination.
ELISA—Serum was collected from Mta2 null and control
mice of different ages. Serum anti-dsDNA, anti-Sm, anti-
SSA, and anti-SSB antibodies levels were measured using
ELISA kits from Alpha Diagnostics International Inc. (San
Antonio, TX).
Flow Cytometry Analysis of Lymphoid Population—Age-
matched conventionalMta2null, T cell-specific null, and age- and
sex-matched control mice were used for analysis. Single cell sus-
pensions of thymocytes, spleen cells, and lymph node (LN) cells
were stained with fluorescein isothiocyanate (FITC)-, phyco-
erythrin (PE)-, peridinin chlorophyll protein (PerCP)-, and allo-
phycocyanin (APC)-conjugated monoclonal antibodies and ana-
lyzedwith FACSCalibur (BDBiosciences). All the antibodies used
for immunostaining were purchased from BD Biosciences. Data
were analyzed using SUMMIT software.
T Cell Proliferation, Th Polarization, and Cytokine Assay—T
cell proliferation assay was performed using a previously
described protocol (29). Briefly, cervical, umbilical, and axial
lymph nodes from each mouse were harvested and pooled.
About 5 105 LN cells or 1 105 purified CD4CD25T cells
were plated in each well of a 96-well plate. The plate was previ-
ously coated with goat anti-hamster antibody (10g/ml). Thir-
ty-six to 48 h later, the cells were pulsed with [3H]thymidine
and harvested after 12 h of incubation. For cytokine production
assay, about 2  106 anti-CD3/anti-CD28 mAb-stimulated LN
cells were plated in a 24-well plate and cultured for 4 days
before harvesting of the supernatant. The cytometric bead
array was performed according to manufacturer’s instruction
(BD Biosciences). For Th differentiation, CD4 T cells were
purified from pooled spleen and LN cells using the CD4 puri-
fication kit follow up AutoMACSTM cell separation (Miltenyi
Biotec Inc., Auburn, CA). 2  106 CD4 cells were stimulated
with anti-CD3 and anti-CD28 mAb, as described, in the pres-
ence of recombinant human IL-2 (100units/ml) (nonpolarized
condition). In addition, for Th1 differentiation, cells were stim-
ulated in the presence of recombinant mouse IL-12 (5 ng/ml)
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and anti-IL-4 (4 g/ml) (Pharmin-
gen). For Th2 differentiation, cells
were stimulated in the presence of
mouse IL-4 (50 ng/ml), anti-IL-12 (5
g/ml), and anti-IFN- (4 g/ml)
mAbs (Pharmingen). After 7 days of
culture, cells were washed and stim-
ulated with phorbol 12-myristate
13-acetate (10 ng/ml) and ionomy-
cin (1 M) for 6 h in the presence of
BD GolgiPlug containing brefeldin
A (Pharmingen) for the last 4 h. IL-4
and IFN- expression was assessed
by intracellular staining. Harvested
cells were stained with anti-CD4
mAb, permeabilized with BD FACS
Permeabilizing Solution 2 (BD Bio-
science), and stained with anti-IL4
and anti-IFN- mAbs. Samples
were fixed with 1% paraformalde-
hyde and analyzed by FACSscan
(BD Bioscience). 1  105 cells from
each polarization condition were
harvested and analyzed for IL-4
expression by real-time PCR.
Reconstituted SCID Mice—To
reconstitute SCID mice, bone mar-
row (BM) cells from 11-week-old
Mta2 WT and Mta2 null mice were
injected into irradiated (250R) SCID-
NOD mice (5  106 bone marrow
cells per mouse). LN T cells in the
reconstituted mice were harvested at
8 weeks post-reconstitution, and
standard FACS and T cell prolifera-
tion assays were performed.
Quantitative Real-time PCR—
Total RNA was extracted using the
Qiagen RNeasy mini kit as per the
manufacturer’s instructions. RNAs
weredenatured for 3min at 70 °Cand
cDNAs were synthesized in Ambion
RT buffer with random decamers
and 100 units of Moloney murine
leukemia virus reverse tran-
scriptase (Invitrogen) for 1 h at
42 °C followed by 10 min at 95 °C to inactivate the enzyme.
Real-time PCR analysis was performed using TaqMan prim-
er/probe mixtures (Applied Biosystems) as recommended by
the manufacturer and analyzed on an Applied Biosystems
7900HT system.
Chromatin Immunoprecipitation (ChIP) Assay—The ChIP
assaywasmodified fromapreviously described protocol (24). The
peripheral T cellswere purified by theCD4Tcell purification kit
(Miltenyi Biotec Inc., Auburn, CA). IL-4 PCR primers were: 1 for-
ward GCCAATCAGCACCTCTCTTC, 1 reverse, TAAAGCCT-
CATTCCATGGTC; 2 forward, CATCGCTACACCTCCCAC, 2
reverse, CCTTGGTTTCAGCAACTTTAAC.
FIGURE 1. Generation of Mta2 mutant mice. A, schematic representation of the Mta2 wild-type locus, the
targeting vector, the Mta22lox allele, and the Mta21lox allele. The targeting vector contains two loxP sites (open
triangle) that flank exons 4 to 11, and two expression cassettes, PGK-Neo and MC1-TK for positive and negative
selection in ES cells. After the targeting construct is electroporated into ES cells, homologous recombination
events were analyzed by PCR with two primer sets indicated as a and b. A third set of primers, c, is used to screen
the Mta21lox allele, which is generated after Cre-mediated loxP recombination occurs in the Mta22lox allele.
Cre-mediated excision of exons 4 –11 generates a frameshift in exon 12. As a result, the mutant transcript only
encodes the 63 N-terminal amino acids of Mta2. B, the three alleles of Mta2, namely, the wild-type allele (/),
the Mta22lox allele, and the Mta21lox allele are distinguished by PCR. C, Western blot analysis with anti-Mta2
antibody using liver protein extracts from wild-type (/), heterozygous (/), and Mta2 knock-out mice
(/). Mta2 protein was not detectable in Mta2 null mice. Tubulin was used as a loading control.
TABLE 1
Inactivation of the Mta2 gene causes partial embryonic lethality
Numbers and percentages of newborn mice with three possible Mta2 genotypes
(/, /, and /) fromMta2/ breeding pairs or maleMta2/ and female
Mta2/ breeding pairs. The percentages of newborn Mta2/ mice are signifi-
cantly lower thanMendelian distribution (p 0.01), indicating someMta2/mice
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Statistics—Chi-square tests were used for genotype distribu-
tion analysis. T tests were used for statistical analysis of mouse
bodyweight, different type of T cell analysis, and T cell prolif-
eration assay.Wilcoxon rank test was used for survival analysis.
RESULTS
Generation of theMta2MutantMice—Although the compo-
sition and biochemical properties of the mammalian NuRD
complex have been extensively characterized (4), its biological
function is not well understood. To gain insight into its func-
tion, we generated amousemodel in which a component of the
NuRD complex is deleted by gene targeting. We chose to inac-
tivate Mta2 because the protein encoded by this gene appears
to be present only in the NuRD complex. We made a condi-
tional gene targeting vector in which Mta2 exons 4–11 were
flanked by two loxP sites (Fig. 1A). Cre-mediated recombina-
tion at these two loxP sites resulted in deletion of exons 4–11
and a frameshift in exon 12. As a result, the Mta2 mutant allele
FIGURE 2. Adult Mta2 knock-out (KO) mice exhibit autoimmunity-related phenotypes in multiple organs. A, upper panels, Mta2 KO mice show skin lesions at
eyelid, mouth, nose, and neck area as indicated by arrows; lower panels, hemotoxylene and eosin (H&E) staining of skin sections from wild-type and Mta2 null mice
show significant hyperkerotosis (arrow) and epidermal cell hyperplasia (acanthosis) (arrowheads) in Mta2 null mice. B, upper panels, H&E-stained kidney sections of
Mta2 null mice reveal mesangial cell proliferation (arrowhead); lower panels, Mta2 null mice also show lymphocyte infiltration (arrow) in kidney. C, Mta2 null mice
develop liver inflammation. H&E-stained liver sections of Mta2 null mice reveal lymphocyte infiltration (lower panel, arrowhead). Portal veins are indicated by arrows.
D, comparison of the liver enzyme activity levels in serum measured by ELISA. Mta2 null mice had a significantly increased alanine aminotransferase (ALT) level (p 
0.01), indicating liver cell damage in these mice. The mutant mice showed no significant change in the levels of aspartate aminotransferase (AST) and alkaline
phosphatase (ALP) in the serum of Mta2 null mice when compared with the wild-type mice. Asterisk indicates the difference is statistically significant.
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would only encode the N-terminal 63 amino acids of the Mta2
protein (Fig. 1A). To investigate the function of Mta2 in whole
animal, theMta22lox/ mice were crossed with EIIa-Cre trans-
genicmice. TheMta21lox mice carrying one completely recom-
bined allele (equal to conventional heterozygous knock-out
mice) were selected for breeding. The Mta21lox mice will be
referred to as Mta2 heterozygous mice and the Mta21lox/1lox
mice will be referred to asMta2 null orMta2 conventional null
mice in this report. As shown in Fig. 1B, theMta22lox,Mta21lox,
and Mta2 wild-type allele can be distinguished by PCR. West-
ern blot analysis of protein extracts derived fromMta2 knock-
out mice confirmed the lack of Mta2 protein (Fig. 1C).
Mta2 Knock-outMice Exhibit Multiple Phenotypes Including
Lupus-like Autoimmune Diseases—Inactivation of the Mta2
gene caused embryonic and perinatal lethality in about half of
Mta2 null mice. Fewer than 50% of Mta2 null mice (in 129/
C57/B6 mixed genetic background) survived to adulthood
(Table 1). Backcross of theMta2 null mice onto a C57/B6 back-
ground caused more severe embryonic lethality. The Mta2
knock-out embryos exhibited defects in axial skeleton, skin,
and craniofacial structure with dif-
ferent penetrance (data not shown).
The Mta2 null mice that survived
postnatally exhibited smaller body
size and female infertility.
Adult Mta2 mice also developed
erosive skin lesions at multiple loca-
tions with high penetrance. More
than 90% of the Mta2 null mice
showed periorbital erosion by 1
month of age (Fig. 2,A and B). From
4months of age, 75% ofMta2 null
mice developed additional skin
lesions in areas surrounding the
mouth and nose, and about 30% of
Mta2 null mice showed skin lesions
in the neck region (Fig. 2A, upper
panels). Histological sections of skin
from the neck lesions of the Mta2
mutant mice revealed hyperkerato-
sis and acanthosis of epidermal
cells, as well as a chronic inflamma-
tory response (Fig. 2A, compare two
lower panels). The periorbital skin
from null mice also showed hyperk-
eratosis and inflammation. In some
regions there were immature hair
follicles and a reduced number of
hair follicles although frank alopecia
was not evident at these early stages.
Often there was evidence of dermal
and subcutaneous inflammation
(panniculitis) and the overall
changes could be characterized as a
chronic spongiotic dermatitis. The
similarity between the skin lesions
ofMta2 null mice and those of mice
with lupus-like autoimmune disease
(30, 31) implies possible defects in the immune system of the
Mta2 null mice.
A histological examination of internal organs revealed that
most Mta2 null mice developed global mesangial cell prolifer-
ation in kidney (Fig. 2B, compare upper panels) and some of
them also showed a significant lymphocyte-rich chronic
inflammatory cell infiltration (Fig. 2B, compare lower panels).
These renal abnormalities are consistentwith histopathological
changes occurring with glomerulonephritis seen in murine
lupus models. Consistent with above symptoms observed in
Mta2 null kidneys, about 40% of adult Mta2 knock-out mice
showed moderate (30 mg/dL) or high (100 mg/dL) urine
protein levels (n 	 20). Control mice showed only trace or neg-
ative urine protein levels. This phenotype is more severe in
female null mice than in the male null mice. In addition, liver
inflammation was also found in more than half of the adult
Mta2 null mice. The lymphocyte infiltration was generally lim-
ited to the portal regions (Fig. 2C).
Consistent with injury to hepatocytes in theMta2 null mice,
ELISA results showed that the serum alanine aminotransferase
FIGURE 3. Mta2 null mice develop lupus specific autoantibodies. A, production of anti-dsDNA antibody is
detected by the Crithidia Luciliae assay that showed positive anti-dsDNA antibody in the Mta2 null serum but
not wild-type serum. B, ELISA analysis demonstrates significantly elevated levels of different autoantibodies,
including anti-dsDNA, anti-Sm, anti-SSA, and anti-SSB, in Mta2 null mice when compared with those of wild-
type mice (p  0.02). C, bodyweight of 2-month-old wild type and Mta2 null mice are plotted according to their
genders. The average bodyweight of null mice is about 75% of that of their wild-type litter mates. D, Kaplan-
Meier survival analysis of Mta2 null and control mice. Mta2 null mice have much shorter lifespans when com-
pared with wild-type or heterozygous mice. Female null mice have a shorter lifespan than the male null mice
that is similar to what have been observed in lupus patients and murine lupus models. Asterisk indicates the
difference is statistically significant (p  0.05).
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activity level is increasedwhen comparedwith that of wild-type
and heterozygous littermates (Fig. 2D). However, the activity
levels of serum aspartate aminotransferase and alkaline phos-
phatase did not exhibit a significant difference between wild-
type andMta2 null mice (Fig. 2D).
To further characterize the autoimmune disease observed in
Mta2 null mice, we collected serums from mutant and control
mice at different ages and examined them for the different
autoantibodies. The Crithidia Luciliae assay demonstrated the
presence of anti-dsDNA antibody in theMta2 null serum (Fig.
3A). ELISA analysis showed significantly higher levels of anti-
dsDNA, anti-Sm, anti-SSA, and anti-SSB antibodies (Fig. 3B).
No difference in autoantibody level had been observed between
Mta2 heterozygous mice and wild-typemice. Anti-dsDNA and
anti-Sm antibodies are markers of human andmurine systemic
lupus erythematosus (SLE), and anti-SSA and anti-SSB anti-
bodies are often evident with Sjogren disease or SLE.
Furthermore, Mta2 null mice are smaller than their litter-
mates. The extent of difference depends on mouse develop-
ment stages. From perinatal to weaning stage, Mta2 null mice
are about half to 2/3 size of the heterozygous or wild-type lit-
termates. When they reach mature age (after 2 months old),
bothmale and female nullmice are about 75%of the size of their
wild-type littermates (Fig. 3C).Mta2 null mice also have short-
ened lifespans when compared with their wild-type or het-
erozygous littermates (Fig. 3D). Interestingly, female knock-out
mice exhibit a shorter lifespan than
male knock-out mice. Given that
90% of SLE patients are female (32),
and some lupus mouse models have
shown more severe phenotype in
females than in males (33, 34), it is
very likely that autoimmune-related
symptoms are important factors
causing early death in Mta2 null
mice. However, our results do not
exclude other factors in causing pre-
mature death. In summary, our
observations strongly suggest that
Mta2 null mice develop an autoim-
mune disease that resembles sys-
temic lupus erythematosus in
human.
Bone Marrow Transplantation
Recipient Mice Partially Recapitu-
late the Autoimmune Phenotypes—
To test if the autoimmune pheno-
types observed in the Mta2 null
mice is caused by bone marrow
derived from Mta2 null cells; we
transferredMta2 null bone marrow
progenitor cells into SCIDmice and
monitored hematopoietic reconsti-
tution over time. No significant
defects were observed in lymphoid
and myeloid reconstitution with
Mta2 mutant progenitor cells (data
not shown). However, recipient
mice transplanted withMta2 null hematopoietic stem and pro-
genitor cell developed skin lesions and reduced body weight
(Fig. 4, A and B), similar to Mta2 null mice. When mice were
analyzed 8–12 weeks post bone marrow transplantation, nor-
mal T cells were present in the thymus and peripheral lymphoid
organs (Fig. 4C). However, theseMta2 null T cells were hyper-
proliferative when stimulated with T cell mitogens (Fig. 4D).
The phenotypes are, however, less severe compared withMta2
null mice, and no obvious liver inflammation or glomerulone-
phritis was detected in the transplanted mice. No increased
level of autoantibodies was observed either (data not shown).
These results indicate that hematopoietic cells derived from
Mta2 null bone marrow stem cells contribute to but are not
sufficient to cause the autoimmune diseases. Therefore, non-
hematopoietic cells must have also contributed to the autoim-
mune phenotypes ofMta2 null mice.
T Cell Hyperproliferation in Mta2 Null Mice—The autoim-
mune phenotypes described above and previous reports on epi-
genetic regulation in T cell development and differentiation by
someNuRD components prompted us to investigate possible T
cell defects in Mta2 null mice. We found that Mta2 null mice
exhibited normal T cell developments in thymus and periph-
eral lymphoid organs (Fig. 5A). The development of
FoxP3CD4CD25Treg cells and their functions are also not
affected by loss of Mta2 (data not shown). Our data also indi-
cated that the ratio of naı̈ve T cells and memory T cells in
FIGURE 4. Mta2-deficient BM cells cause decreased bodyweight, skin lesion, and T cell hyperprolifera-
tion in recipient SCID mice. A, the transfer of BM cells from Mta2 knock-out (KO) mice cause 25% decreased
bodyweight in recipient SCID mice 8 weeks after bone marrow transplantation (p  0.03). B, a representative
SCID mouse received Mta2 KO BMT showed skin lesion (upper mouse), whereas the representative SCID mouse
received BMT from wild-type mice exhibited normal skin (lower mouse) 8 weeks after transplantation. In this
experiment, all three SCID mice that received Mta2 KO BM cells developed skin lesion and none of the four SCID
mice received wild-type BM cells developed skin lesion. C, FACS analysis indicated that transplanted Mta2 KO
BM cells successfully reconstituted in T cells in SCID mice. The relative reconstitution of T cells from Mta2 KO
BMT SCID mice and WT BMT SCID mice were plotted (n 	 3 for each genotype). D, the LN cells from Mta2
KO BMT SCID mice showed hyperproliferation upon different concentrations of concanavalin A (ConA) stimu-
lation. Asterisk indicates the difference is statistically significant (p  0.05).
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Mta2-deficient peripheral lymphoid organs was normal (Fig.
5A). However, when stimulated with anti-CD3, or anti-CD3 in
combination with anti-CD28 mAbs, Mta2-deficient T cells
from LNwere hyperproliferative compared with the LN T cells
from control mice (Fig. 5B) (n 	 7
for each genotype). Furthermore,
purified CD4CD25 peripheral T
cells from Mta2 null mice also
showed hyperproliferation in
response to TCR stimulation (Fig.
5C). To evaluate whether the
observed hyperproliferation is T cell
autonomous, we have generated
LckCre, Mta22lox/1lox, and LckCre,
Mta22lox/2lox mice that exhibit Mta2
genedeletion inTcells. Similar to that
observed in the conventional Mta2
null mice, T cells from T cell-specific
Mta2 null (TKO) mice also exhibited
hyperproliferation uponT cell activa-
tion (Fig. 5D). However, no other
autoimmune phenotypes were
observed in these mice (data not
shown), suggesting that non-T cells
must have contributed to the autoim-
mune disease in the Mta2 conven-
tional null mice.
To understand the molecular
basis of T cell hyperproliferation
in response to Mta2 inactivation,
we analyzed the effects of Mta2
inactivation on the levels of vari-
ous cytokines induced by the LN-
derived lymphocytes. Results
shown in Fig. 5E indicate that
Mta2 null T cells produced more
IL-2, IL-4, and IFN- than control
cells when stimulated with anti-
CD3 and anti-CD28 mAbs, con-
sistent with hyperproliferation of
Mta2 null T cells.
Mta2 Regulates IL-4 and IFN-
Production under Th2 Conditions—
In response to Mta2 inactivation,
both IFN- and IL-4 were hyper-
induced in TCR-activated T cells
(Fig. 5E). Given that epigenetic
mechanisms are involved in
silencing IL-4 and IFN- during T
cell activation under Th1 or Th2
conditions, respectively (21–23),
we asked whetherMta2 is involved
in silencing of the IL-4 and IFN-
genes under Th1 or Th2 condi-
tions. Results shown in Fig. 6A
indicateMta2 inactivation did not
affect Th1 polarization, suggesting
that Mta2 is not involved in mod-
ulating IL-4 or IFN- expression during Th1 responses.
However, expression of both IL-4 and IFN- in Mta2 null T
cells was elevated under Th2 conditions when compared
with that of wild-type T cells (Fig. 6B). These results suggest
FIGURE 5. Inactivation of Mta2 gene causes intrinsic T cell hyperproliferation. A, Mta2 null mice showed
normal peripheral T cell development. Representative plots of FACS analysis for CD4/CD8 expression on LN
cells (upper) and CD44/CD25 (lower) expression on CD4 LN cells. B, Mta2 null LN cells are hyperproliferative in
response to anti-CD3, or anti-CD3 and anti-CD28 mAb stimulation (p  0.01). Heterozygous littermates were
used as controls because no significant difference between heterozygous and wild-type mice has been
observed. Data were collected from 5 independent experiments (n 	 7 for each genotype). The average value
obtained from heterozygous LN cells in each experiment is normalized to 1. C, peripheral CD4CD25 T cells
were purified from Mta2 null and wild-type mice, and then incubated and stimulated with anti-CD3 or anti-CD3
and anti-CD28 mAb antibodies. Mta2 null CD4CD25 T cells were hyperproliferative compared with wild-
type CD4CD25 T cells. D, T cells from T cell-specific knock-out (KO) mice are hyperproliferative. LN cells from
LckCre,Mta22lox/lox mice and LckCre,Mta22lox/2lox mice and TKO are hyperproliferative when compared with LN
cells from control mice (Con.) under concanavalin A (ConA) stimulation (n 	 4 for each genotype, p  0.05).
Control mice include LckCre, Mta22lox/, and Mta22lox/ mice. E, cytokine analysis showed increased secretion
of IL-2, IL-4, and IFN- by the Mta2 null T cells upon anti-CD3/anti-CD28 mAb stimulation, but no significant
difference has been observed in terms of the level of IL-5 or TNF- (n 	 2 for each genotype). Asterisk indicates
the difference is statistically significant (p  0.05).
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that Mta2 is involved in suppressing expression of both IL-4
and IFN- during Th2 responses.
IL-4 Is a Direct Target of Mta2—Considering the fact that
Mta2/NuRD is a co-repressor complex (8, 14), one likely expla-
nation for the increased production of cytokines byMta2 null T
cells is increased transcription of these genes caused by inacti-
vation of the co-repressor complex. To explore this possibility,
we analyzed the effects ofMta2 inactivation on the expression
of IL-4under stimulation by real-timePCR.Consistentwith the
increase in the protein levels (Figs. 4E and 6B), inactivation of
Mta2 also resulted in an increase in the IL-4 mRNA level (Fig.
6C). To determine whether the IL-4 gene is a direct target of
Mta2/NuRD, ChIP assays were performed using a polyclonal
antibody against Mta2 in activated T cells. As a control for
antibody specificity, rabbit IgG was also included in a parallel
experiment. Data shown in Fig. 6D demonstrate that Mta2
binds to the promoter and downstream of the transcription
start site (lanes 2 and 5). The ChIP signal is specific because a
parallel ChIP assay usingMta2 null cells did not enrich binding
of Mta2. Based on these results, we conclude that the IL-4 gene
is a direct target of the Mta2-NuRD complex. The elevated
expression of IFN- under Th2 conditions suggests that Mta2/
NuRD likely suppress IFN- gene expression. However, we
failed to detect direct binding of
Mta2 to the IFN- promoter region
(data not shown).
DISCUSSION
NuRD is a multisubunit protein
complex that includes: Mta2,
Mbd3, and Mi-2, HDAC1/2 and
RbAp46/48 (4, 9). NuRD is unique
because it possesses both histone
deacetylase and chromatin re-
modeling activities. To under-
stand the in vivo function of this
interesting complex, mice defi-
cient in Mbd3 and Mi-2, respec-
tively, have been generated and
characterized. Loss of Mbd3 func-
tion results in embryonic lethality
and loss of ES cell pluripotency,
suggesting a key function of NuRD
in maintaining ES cell pluripo-
tency and early embryogenesis
(15, 16, 35). The phenotypes of T
cell-specific Mi-2 knock-out
revealed a critical role forMi-2 in
regulating CD4 gene expression.
However, instead of being a com-
ponent of the NuRD co-repressor
complex, Mi-2 appeared to acti-
vate CD4 expression in T cells by
association with p300 and HeLa
E-box-binding protein (HEB) at
the CD4 enhancer (36). Therefore,
the Mta2 knock-out mouse model
presented here is the first model
for understanding the function of the NuRD complex
beyond embryonic development.
Based on production of autoantibodies, glomerulonephritis,
skin lesions, and liver symptoms (Figs. 2 and 3), we conclude
that Mta2 null mice develop lupus-like autoimmune disease.
Systemic lupus erythematosus is a major autoantibody-medi-
ated autoimmune disease. Until now, the etiology of SLE
remains unclear. Many knock-out and transgenic mouse mod-
els have provided important insights into the cellular and
molecular mechanisms underlying lupus, and can be used to
test potential lupus drugs. Genes that play important roles in
SLE can be largely classified into several functional groups
including: 1) apoptosis related, e.g. Fas, Fas-L, and Bcl-2; 2) T
cell activation related, e.g. CTLA4, PD1, and gadd45; 3) B cell
activation related, e.g. Blys, Fyn, and Btk; and 4) phagocytosis
and debris clearance related, e.g. c-Mer and DNase I, and tran-
scription factors such as Aiolos. The Mta2 knock-out model
described here is the first model to show that defects in chro-
matin remodeling and histone modification also cause lupus-
like disease.
Inactivation of Mta2, although not affecting T cell develop-
ment, causes T cell hyperproliferation upon TCR-mediated
stimulation. Because the percentages of the naı̈ve T cells, regu-
FIGURE 6. IL-4 is a direct target of Mta2. A, normal Th1 polarization in Mta2 null cells. B, loss of Mta2 function
results in increased IFN- and IL-4 under Th2 conditions. Results of FACS analysis are shown on A and B as bar
graphs representing percentage of IFN- and IL-4 gated on CD4 cells. Data presented are an average of 3
mice per genotype from two independent experiments. Standard deviation is shown as error bars. C, real-time
reverse transcriptase-PCR results of IL-4 expression levels in cells activated under non-polarizing, Th1 or Th2
conditions. Results are expressed as the ratio of IL-4 over 18 S to control for amounts of cDNA analyzed (p 
0.01). D, ChIP assays demonstrate that Mta2 is localized to the IL-4 gene in the wild-type, but not in the Mta2 null
mice. Exons are indicated by black strips. Asterisk indicates the difference is statistically significant (p  0.05).
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latory T cells, andmemory T cells in peripheral are not affected
by Mta2 inactivation (Fig. 5A and data not shown), it is likely
thatMta2may be involved in controlling the threshold of T cell
proliferation upon stimulation. This T cell phenotype has been
observed in purified native CD4 T cells, in T cell-specificMta2
nullmice, and in T cells fromBMTSCIDmice, suggesting a cell
autonomous hyperproliferation. Consistent with this possibil-
ity, Mta2 null mice exhibited autoimmune phenotypes. It is
worth noting that Mta2 null-BMT mice and TKO mice only
recapitulate some of theMta2 null mice phenotypes, indicating
that non-hematopoietic cells or non-T cells also contribute to
the observed autoimmune disease in Mta2 null mice. In a dif-
ferent study, we have found thatMta2 null B cells exhibit severe
developmental and differentiation defects (data not shown).
However, those defects seem not to contribute to the autoim-
mune phenotypes observed inMta2 null mice as B cell-specific
knock-out mice do not exhibit any of the autoimmune pheno-
types observed inMta2 conventional null mice.
In this study, we provide evidence supporting a role forMta2
in modulating cytokine gene expression during T cell activa-
tion. It inhibits IL-4 expression in Th2 cells, as a potential
mechanism to prevent overproduction of IL-4 and Th2-related
autoimmunity. In addition, we also demonstrate that IL-4 is a
direct target of Mta2 in T cells. Because Mta2 facilitates
deacetylase activity of the NuRD complex (37), our observation
that the IL-4 expression level is increased inMta2 null T cells is
consistentwith the role ofNuRDas a co-repressor. Future stud-
ies will address: (a) whether histone acetylation level at IL-4
promoter is affected; (b) whether other components of NuRD
are localized at this locus; and (c) whether Mta2 deficiency
affects chromatin remodeling activity of NuRD. Our data sug-
gest that an Mta2-independent mechanism must be responsi-
ble for silencing the IL-4 gene in Th1 cells. Our studies also
indicate that Mta2/NuRD has a role in suppressing IFN-
expression in Th2 cells. In Th2 cells, elevated IFN- is
expressed in the presence of higher levels of IL-4, although
direct binding of Mta2 to the IFN- gene is not detected. Thus,
Mta2may participate in suppressing IFN- gene expression via
indirect mechanisms. Further characterization of other
immune cell types in theMta2 null mice, identification ofmore
Mta2/NuRD target genes, and epigenetic change occurred at
the regulatory regions of these geneswill give us a better picture
of the role of Mta2/NuRD in the mammalian immune system.
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